Vericiguat for Post-Myocardial Infarction Heart Failure Prevention: From Molecular Mechanisms to Clinical Translation

Jannat Atajanova; Shiraz Rafiq; Guiqiu Cao

doi:10.2478/rjc-2026-0025

.blurhash-client-img { display: none !important; }

Vericiguat for Post-Myocardial Infarction Heart Failure Prevention: From Molecular Mechanisms to Clinical Translation

Romanian Journal of Cardiology

AHEAD OF PRINT

By: Jannat Atajanova, Shiraz Rafiq and Guiqiu Cao

Open Access

|Sep 2026

Khan MA, Hashim M. J, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020;12(7):e9349. . doi:10.7759/cureus.9349.
Open DOI Search in Google Scholar Back to article
GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2162–2203. doi:10.1016/S0140-6736(24)00933-4. Erratum in: Lancet. 2024 Jul 20;404(10449):244. doi:10.1016/S0140-6736(24)01458-2.
Open DOI Search in Google Scholar Back to article
Salari N, Morddarvanjoghi F, Abdolmaleki A, Rasoulpoor S, Khaleghi AA, Hezarkhani LA, et al. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023;23(1):206. doi:10.1186/s12872-023-03231-w.
Open DOI Search in Google Scholar Back to article
Safiri S, Karamzad N, Singh K, Carson-Chahhoud K, Adams C, Nejadghaderi SA, et al. Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990–2019. Eur J Prev Cardiol. 2022;29(2):420–431. doi:10.1093/eurjpc/zwab213.
Open DOI Search in Google Scholar Back to article
Jenča D, Melenovský V, Stehlik J, Staněk V, Kettner J, Kautzner J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8(1):222–237. doi:10.1002/ehf2.13144.
Open DOI Search in Google Scholar Back to article
Jiang H, Fang T, Cheng Z. Mechanism of heart failure after myocardial infarction. J Int Med Res. 2023;51(10):3000605231202573. doi:10.1177/03000605231202573.
Open DOI Search in Google Scholar Back to article
Leancă SA, Crișu D, Petriș AO, Afrăsânie I, Genes A, Costache AD, et al. Left ventricular remodeling after myocardial infarction: from physiopathology to treatment. Life (Basel). 2022;12(8):1111. doi:10.3390/life12081111.
Open DOI Search in Google Scholar Back to article
Darvish M, Shakoor A, Feyz L, et al. Heart failure: assessment of the global economic burden. Eur Heart J. 2025;46(31):3069–3078. doi:10.1093/eurheartj/ehaf323.
Open DOI Search in Google Scholar Back to article
Gerber Y, Weston SA, Enriquez-Sarano M, Berardi C, Chamberlain AM, Manemann SM, et al. Mortality associated with heart failure after myocardial infarction: a contemporary community perspective. Circ Heart Fail. 2016;9(1):e002460. doi:10.1161/CIRCHEARTFAILURE.115.002460.
Open DOI Search in Google Scholar Back to article
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191.
Open DOI Search in Google Scholar Back to article
Bucholz EM, Butala NM, Normand ST, Wang Y, Krumholz HM. Association of guideline-based admission treatments and life expectancy after myocardial infarction in elderly medicare beneficiaries. J Am Coll Cardiol. 2016;67(20):2378–2391. doi:10.1016/j.jacc.2016.03.507.
Open DOI Search in Google Scholar Back to article
Zodda E, Tura-Ceide O, Mills NL, Tarragó-Celada J, Carini M, Thomson TM, et al. Autonomous metabolic reprogramming and oxidative stress characterize endothelial dysfunction in acute myocardial infarction. Elife. 2023;12:e86260. doi:10.7554/eLife.86260.
Open DOI Search in Google Scholar Back to article
De Feo D, Massari F, Campanella C, Livrieri A, Ciccone MM, Caldarola P, et al. Influence of soluble guanylate cyclase on cardiac, vascular, and renal structure and function: a physiopathological insight. Int J Mol Sci. 2025;26(10):4550. doi:10.3390/ijms26104550.
Open DOI Search in Google Scholar Back to article
Blanton RM. cGMP signaling and modulation in heart failure. J Cardiovasc Pharmacol. 2020;75(5):385–398. doi:10.1097/FJC.0000000000000749.
Open DOI Search in Google Scholar Back to article
Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, et al. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022;24(11):2029–2036. doi:10.1002/ejhf.2720.
Open DOI Search in Google Scholar Back to article
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893. doi:10.1056/NEJMoa1915928.
Open DOI Search in Google Scholar Back to article
Cai Y, Zhang B, Shalamu A, Gao T, Ge J. Soluble guanylate cyclase (sGC) stimulator vericiguat alleviates myocardial ischemia-reperfusion injury by improving microcirculation. Ann Transl Med. 2022;10(12):662. doi:10.21037/atm-22-2583.
Open DOI Search in Google Scholar Back to article
Faridi KF, Bhalla N, Atreja N, Venditto J, Khan ND, Wilson T, et al. New heart failure after myocardial infarction (from the National Cardiovascular Data Registries [NCDR] linked With all-payer claims). Am J Cardiol. 2021;151:70–77. doi:10.1016/j.amjcard.2021.04.019.
Open DOI Search in Google Scholar Back to article
Gawrys, O, Kala P, Šnorek M, Melenovský V, Corda S, Sandner. Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure. Biochem pharmacol. 2025;242(Pt 3):117363. doi:10.1016/j.bcp.2025.117363.
Open DOI Search in Google Scholar Back to article
Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, et al. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev. 2017;2017:3920195. doi:10.1155/2017/3920195.
Open DOI Search in Google Scholar Back to article
Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43(27):2549–2561. doi:10.1093/eurheartj/ehac223.
Open DOI Search in Google Scholar Back to article
Marcos-Garcés V, Bertolín-Boronat C, Merenciano-González H, Martínez Mas ML, Climent Alberola JI, López-Bueno L, et al. Left ventricular remodeling after myocardial infarction-pathophysiology, diagnostic approach and management during cardiac rehabilitation. Int J Mol Sci. 2025;26(22):10964. doi:10.3390/ijms262210964.
Open DOI Search in Google Scholar Back to article
Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:73–87. doi:10.1016/j.pharmthera.2018.01.001.
Open DOI Search in Google Scholar Back to article
Yong J, Tao J, Wang K, Li X, Yang Y. Post-myocardial infarction cardiac remodeling: multidimensional mechanisms and clinical prospects of stem cell therapy. Stem Cell Rev Rep. 2025;21(5):1369–1427. doi:10.1007/s12015-025-10888-7.
Open DOI Search in Google Scholar Back to article
Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16(1):13–21. doi:10.1007/s10741-010-9181-7.
Open DOI Search in Google Scholar Back to article
Zhao W, Zhao J, Rong J. Pharmacological modulation of cardiac remodeling after myocardial infarction. Oxid Med Cell Longev. 2020;2020:8815349. doi:10.1155/2020/8815349.
Open DOI Search in Google Scholar Back to article
Janssens KLPM, Kraamer M, Barbarotta L, Bovendeerd PHM. Post-infarct evolution of ventricular and myocardial function. Biomech Model Mechanobiol. 2023;22(6):1815–1828. doi:10.1007/s10237-023-01734-1.
Open DOI Search in Google Scholar Back to article
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25):2981–2988. doi:10.1161/01.cir.101.25.2981.
Open DOI Search in Google Scholar Back to article
Udelson JE, Konstam MA. Ventricular remodeling fundamental to the progression (and regression) of heart failure. J Am Coll Cardiol. 2011;57(13):1477–79. doi:10.1016/j.jacc.2011.01.009.
Open DOI Search in Google Scholar Back to article
Gombozhapova A, Rogovskaya Y, Shurupov V, Rebenkova M, Kzhyshkowska J, Popov SV, et al. Macrophage activation and polarization in post-infarction cardiac remodeling. J Biomed Sci. 2017;24(1):13. doi:10.1186/s12929-017-0322-3.
Open DOI Search in Google Scholar Back to article
Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21):2837–2849. doi:10.1161/CIRCULATIONAHA.104.500546.
Open DOI Search in Google Scholar Back to article
Galli A, Lombardi F. Postinfarct left ventricular remodelling: a prevailing cause of heart failure. Cardiol Res Pract. 2016;2016:2579832. doi:10.1155/2016/2579832.
Open DOI Search in Google Scholar Back to article
Obata JE, Horikoshi T, Nakamura T, Kugiyama K. Sustained endothelial dysfunction in the infarct-related coronary artery is associated with left ventricular adverse remodeling in survivors of ST-segment elevation myocardial infarction. J Cardiol. 2020;75(3):261–269. doi:10.1016/j.jjcc.2019.08.001.
Open DOI Search in Google Scholar Back to article
Sun Y. Oxidative stress and cardiac repair/remodeling following infarction. Am J Med Sci. 2007;334(3):197–205. doi:10.1097/MAJ.0b013e318157388f.
Open DOI Search in Google Scholar Back to article
Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001;104(11):1286–91. doi:10.1161/hc3601.094298.
Open DOI Search in Google Scholar Back to article
Bajec T, Poglajen G. Targeting the NO-sGC-cGMP pathway: mechanisms of action of vericiguat in chronic heart failure. Cells. 2025;14(17):1400. doi:10.3390/cells14171400.
Open DOI Search in Google Scholar Back to article
Zuchi C, Tritto I, Carluccio E, Mattei C, Cattadori G, Ambrosio G. Role of endothelial dysfunction in heart failure. Heart Fail Rev. 2020;25(1):21–30. doi:10.1007/s10741-019-09881-3.
Open DOI Search in Google Scholar Back to article
Mace EH, Kimlinger MJ, Billings FT 4th, Lopez MG. Targeting soluble guanylyl cyclase during ischemia and reperfusion. Cells. 2023;12(14):1903. doi:10.3390/cells12141903.
Open DOI Search in Google Scholar Back to article
French BA, Kramer CM. Mechanisms of post-infarct left ventricular remodeling. Drug Discov Today Dis Mech. 2007;4(3):185–196. doi:10.1016/j.ddmec.2007.12.006.
Open DOI Search in Google Scholar Back to article
Numata G, Takimoto E. Cyclic GMP and PKG signaling in heart failure. Front Pharmacol. 2022;13:792798. doi:10.3389/fphar.2022.792798.
Open DOI Search in Google Scholar Back to article
Trujillo ME, Ayalasomayajula S, Blaustein RO, Gheyas F. Vericiguat, a novel sGC stimulator: mechanism of action, clinical, and translational science. Clin Transl Sci. 2023;16(12):2458–2466. doi:10.1111/cts.13677.
Open DOI Search in Google Scholar Back to article
Tricarico L, Correale M, Bevere EML, Daniele Brunetti N, Iacoviello M. The role of Vericiguat in heart failure therapy: from clinical trials to clinical practice. Rev Cardiovasc Med. 2025;26(8):39886. doi:10.31083/RCM39886.
Open DOI Search in Google Scholar Back to article
Zhao Y, Li H, Wu Z, Wang H, Zhang L, Zhang Y, et al. Vericiguat attenuates post-myocardial infarction inflammation associated with macrophage polarization and regulation of the Survivin/Caspase-6 pathway. FASEB J. 2026;40(6):e71635. doi:10.1096/fj.202501845RRR.
Open DOI Search in Google Scholar Back to article
Inserte J, Garcia-Dorado D. The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism. Br J Pharmacol. 2015;172(8):1996–2009. doi:10.1111/bph.12959.
Open DOI Search in Google Scholar Back to article
Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563–581. doi:10.1007/s00441-016-2431-9.
Open DOI Search in Google Scholar Back to article
Werner F, Prentki Santos E, Michel K, Schrader H, Völker K, Potapenko T, et al. Ablation of C-type natriuretic peptide/cGMP signaling in fibroblasts exacerbates adverse cardiac remodeling in mice. JCI Insight. 2023;8(13):e160416. doi:10.1172/jci.insight.160416.
Open DOI Search in Google Scholar Back to article
Sun X, Sheng Y, Xu P, Peng Q, Ruan Z. Vericiguat reduces atrial fibrillation recurrence by alleviating myocardial fibrosis via the TGF-β1/Smad2/3 pathway. PLoS One. 2025;20(7):e0328272. doi:10.1371/journal.pone.0328272.
Open DOI Search in Google Scholar Back to article
Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res. 2001;88(5):529–535. doi:10.1161/01.res.88.5.529.
Open DOI Search in Google Scholar Back to article
Jungtanasomboon P, Nussaro S, Winwan H, Suebthawinkul P, Boonpala P, Dong VNK, et al. Vericiguat preserved cardiac function and mitochondrial quality in a rat model of mitral regurgitation. Life Sci. 2023;328:121929. doi:10.1016/j.lfs.2023.121929.
Open DOI Search in Google Scholar Back to article
Khounphinith, E, Zhou Y, Yi Z, Li T, Li L. Vericiguat reduces pyroptosis in rats with coronary microembolization by inhibiting the AMPK/Nrf2/NLRP3 signaling pathway. Korean J Physiol Pharmacol. 2025;29(6):755–767. doi:10.4196/kjpp.25.008.
Open DOI Search in Google Scholar Back to article
Fiori E, Davinelli S, Ferrera A, Medoro A, Barsali C, Battistoni A, et al. The emerging role of Nrf2 in heart failure: from cardioprotection to therapeutic approaches. ESC Heart Fail. 2025;12(6):4000–4020. doi:10.1002/ehf2.15406.
Open DOI Search in Google Scholar Back to article
Takahashi M. Role of NLRP3 inflammasome in cardiac inflammation and remodeling after myocardial infarction. Biol Pharm Bull. 2019;42(4):518–523. doi:10.1248/bpb.b18-00369.
Open DOI Search in Google Scholar Back to article
Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res. 2009;104(2):e9–e18. doi:10.1161/CIRCRESAHA.108.188243.
Open DOI Search in Google Scholar Back to article
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539. doi:10.1016/j.jacc.2008.07.051.
Open DOI Search in Google Scholar Back to article
Krishnan, SM, Kraehling JR, Eitner F, Bénardeau A, Sandner P. The impact of the nitric oxide (NO)/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective. Int J Mol Sci. 2018;19(6):1712. doi:10.3390/ijms19061712.
Open DOI Search in Google Scholar Back to article
Liu X, Tang M, Lu J, Kong Y, Shen W, Zhang C, et al. Vericiguat attenuates cyclosporine A-induced nephropathy by targeting the NF-κB/TGF-β1 axis: an integrated network pharmacology, Mendelian randomization, and experimental study. Front Immunol. 2026;16:1756582. doi:10.3389/fimmu.2025.1756582.
Open DOI Search in Google Scholar Back to article
Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(21):2625–2641. doi:10.1016/j.jacc.2018.09.042.
Open DOI Search in Google Scholar Back to article
Vannuccini F, Campora A, Barilli M, Palazzuoli A. Vericiguat in heart failure: characteristics, scientific evidence and potential clinical applications. Biomedicines. 2022;10(10):2471. doi:10.3390/biomedicines10102471.
Open DOI Search in Google Scholar Back to article
Singh A, Ashraf S, Irfan H, Venjhraj F, Verma A, Shaukat A, et al. Heart failure and microvascular dysfunction: an in-depth review of mechanisms, diagnostic strategies, and innovative therapies. Ann Med Surg (Lond). 2024;87(2):616–626. doi:10.1097/MS9.0000000000002971.
Open DOI Search in Google Scholar Back to article
Chen T, Kong B, Shuai W, Gong Y, Zhang J, Huang H. Vericiguat alleviates ventricular remodeling and arrhythmias in mouse models of myocardial infarction via CaMKII signaling. Life Sci. 2023;334:122184. doi:10.1016/j.lfs.2023.122184.
Open DOI Search in Google Scholar Back to article
Kassis-George H, Verlinden NJ, Fu S, Kanwar M. Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations. Ther Clin Risk Manag. 2022;18:315–22. doi:10.2147/TCRM.S357422.
Open DOI Search in Google Scholar Back to article
Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA. 2015;314(21):2251–2262. doi:10.1001/jama.2015.15734.
Open DOI Search in Google Scholar Back to article
Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119–1127. doi:10.1093/eurheartj/ehw593.
Open DOI Search in Google Scholar Back to article
Reddy YNV, Butler J, Anstrom KJ, Blaustein RO, Bonaca MP, Corda S, et al. Vericiguat global study in participants with chronic heart failure: design of the VICTOR trial. Eur J Heart Fail. 2025;27(2):209–218. doi:10.1002/ejhf.3501.
Open DOI Search in Google Scholar Back to article
Bostan MM, Stătescu C, Anghel L, Șerban IL, Cojocaru E, Sascău R. Post-myocardial infarction ventricular remodeling biomarkers-the key link between pathophysiology and clinic. Biomolecules. 2020;10(11):1587. doi:10.3390/biom10111587.
Open DOI Search in Google Scholar Back to article
Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Res Cardiol. 2014;109(4):421. doi:10.1007/s00395-014-0421-1.
Open DOI Search in Google Scholar Back to article
Methner C, Buonincontri G, Hu CH, Vujic A, Kretschmer A, Sawiak S, et al. Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging. PLoS One. 2013;8(12):e83910. doi:10.1371/journal.pone.0083910.
Open DOI Search in Google Scholar Back to article
Dempster T, Corker A, Vu K, Troncoso M, Bradley N, Hazzard A, et al. Modulation of macrophage polarization with acute administration of vericiguat after myocardial infarction. Am J Physiol Heart Circ Physiol. 2026;330(3):H890–H903. doi:10.1152/ajpheart.00626.2025.
Open DOI Search in Google Scholar Back to article
Senni M, Lopez-Sendon J, Cohen-Solal A, Ponikowski P, Nkulikiyinka R, Freitas C, et al. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. ESC Heart Fail. 2022;9(6):3791–3803. doi:10.1002/ehf2.14050.
Open DOI Search in Google Scholar Back to article
Chang PC, Lee HL, Wo HT, Liu HT, Wen MS, Chou CC. Vericiguat suppresses ventricular tachyarrhythmias inducibility in a rabbit myocardial infarction model. PLoS One. 2024;19(4):e0301970. doi:10.1371/journal.pone.0301970.
Open DOI Search in Google Scholar Back to article
Rüdebusch J, Benkner A, Nath N, Fleuch L, Kaderali L, Grube K, et al. Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling. Br J Pharmacol. 2022;179(11):2430–2442. doi:10.1111/bph.15333.
Open DOI Search in Google Scholar Back to article
Silveira CFDSMPD, Malagutte KNDS, Nogueira BF, Reis FM, Rodrigues CDSA, Rossi DAA, et al. Clinical and echocardiographic predictors of left ventricular remodeling following anterior acute myocardial infarction. Clinics (Sao Paulo). 2021;76:e2732. doi:10.6061/clinics/2021/e2732.
Open DOI Search in Google Scholar Back to article
Mao S, Chen P, Pan W, Gao L, Zhang M. Exacerbated post-infarct pathological myocardial remodelling in diabetes is associated with impaired autophagy and aggravated NLRP3 inflammasome activation. ESC Heart Fail. 2022;9(1):303–317. doi:10.1002/ehf2.13754.
Open DOI Search in Google Scholar Back to article
Carlsen CM, Bay M, Kirk V, Gøtze JP, Køber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. Eur J Heart Fail. 2012;14(3):240–247. doi:10.1093/eurjhf/hfs003.
Open DOI Search in Google Scholar Back to article
Yang H, Luo C, Lan WQ, Tang YH. Vericiguat treatment of heart failure: a systematic review and meta-analysis. World J Clin Cases. 2023;11(35):8330–8342. doi:10.12998/wjcc.v11.i35.8330.
Open DOI Search in Google Scholar Back to article
Dudek D, Dziewierz A, Rakowski T, El Masri N, Sorysz D, Zalewski J, et al. Time-to-reperfusion therapy influences outcome of patients with myocardial infarction subjected to facilitated PCI. EuroIntervention. 2005;1(3):309–314.
Search in Google Scholar Back to article
Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255–265. doi:10.1038/nrcardio.2014.28.
Open DOI Search in Google Scholar Back to article
Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161–1172. doi:10.1161/01.cir.81.4.1161.
Open DOI Search in Google Scholar Back to article
Drera A, Rodella L, Brangi E, Riccardi M, Vizzardi E. Endothelial dysfunction in heart failure: what is its role? J Clin Med. 2024;13(9):2534. doi:10.3390/jcm13092534.
Open DOI Search in Google Scholar Back to article
Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122(3):216–238. doi:10.1016/j.pharmthera.2009.02.009.
Open DOI Search in Google Scholar Back to article
Fritsch A, Meyer M, Blaustein RO, Trujillo ME, Kauh E, Roessig L, et al. Clinical pharmacokinetic and pharmacodynamic profile of vericiguat. Clin Pharmacokinet. 2024;63(6):751–771. doi:10.1007/s40262-024-01384-1.
Open DOI Search in Google Scholar Back to article
Yin X, Yin X, Pan X, Zhang J, Fan X, Li J, et al. Post-myocardial infarction fibrosis: pathophysiology, examination, and intervention. Front Pharmacol. 2023;14:1070973. doi:10.3389/fphar.2023.1070973.
Open DOI Search in Google Scholar Back to article
Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, et al. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014;16(5):494–508. doi:10.1002/ejhf.62.
Open DOI Search in Google Scholar Back to article
Correale M, Pelaggi G, Catanoso MC, Miccichè S, Teresi L, Bonanno S, et al. Vericiguat in heart failure with reduced ejection fraction: hope or solid reality? Heart Fail Rev. 2024;29(5):1135–1143. doi:10.1007/s10741-024-10425-7.
Open DOI Search in Google Scholar Back to article
Tang H, Germinal K, Milfort A, Chen WH, Chang SH, Huang W, et al. The most effective combination of pharmacological therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2024;24(1):666. doi:10.1186/s12872-024-04339-3.
Open DOI Search in Google Scholar Back to article
Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropeckyj-Cox D, et al. Biomarker-guided cardioprotection for patients treated with anthracyclines: a randomized clinical trial. JAMA Netw Open. 2025;8(12):e2546201. doi:10.1001/jamanetworkopen.2025.46201.
Open DOI Search in Google Scholar Back to article
Weldy CS, Ashley EA. Towards precision medicine in heart failure. Nat Rev Cardiol. 2021;18(11):745–762. doi:10.1038/s41569-021-00566-9.
Open DOI Search in Google Scholar Back to article
Norre T, Grimm D, Simonsen U. Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic Clin Pharmacol Toxicol. 2022;130(4):425–438. doi:10.1111/bcpt.13714.
Open DOI Search in Google Scholar Back to article
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–767. doi:10.1016/S0140-6736(22)01429-5.
Open DOI Search in Google Scholar Back to article
Zhao D, Zhang Y, Yong Y, Wang L, Liu J. Vericiguat combined with “new quadruple” therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study. Front Cardiovasc Med. 2024;11:1476976. doi:10.3389/fcvm.2024.1476976.
Open DOI Search in Google Scholar Back to article
Falco L, Brescia B, Catapano D, Martucci ML, Valente F, Gravino R, Contaldi C, et al. Vericiguat: the fifth harmony of heart failure with reduced ejection fraction. J Cardiovasc Dev Dis. 2023;10(9):388. doi:10.3390/jcdd10090388.
Open DOI Search in Google Scholar Back to article
Bellis A, Di Gioia G, Mauro C, Mancusi C, Barbato E, Izzo R, et al. Reducing cardiac injury during ST-elevation myocardial infarction: a reasoned approach to a multitarget therapeutic strategy. J Clin Med. 2021;10(13):2968. doi:10.3390/jcm10132968.
Open DOI Search in Google Scholar Back to article
Cacciapuoti F, Mauro C, Capone V, Chianese S, Tarquinio LG, Gottilla R, et al. The role of Vericiguat in early phases of anterior myocardial infarction: a potential game-changer? Medicina (Kaunas). 2024;60(10):1595. doi:10.3390/medicina60101595.
Open DOI Search in Google Scholar Back to article
Chioncel O, Mebazaa A, Farmakis D, Abdelhamid M, Lund LH, Harjola VP, et al. Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2025;27(6):1067–1088. doi:10.1002/ejhf.3673.
Open DOI Search in Google Scholar Back to article
Cowie MR, Schöpe J, Wagenpfeil S, Tavazzi L, Böhm M, Ponikowski P, et al. Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Fail. 2021;8(2):861–871. doi:10.1002/ehf2.13237.
Open DOI Search in Google Scholar Back to article
Varnado S, Ali HR, Trachtenberg B. Medical therapy for heart failure with preserved ejection fraction. Methodist Debakey Cardiovasc J. 2022;18(5):17–26. doi:10.14797/mdcvj.1162.
Open DOI Search in Google Scholar Back to article
Radu AF, Radu A, Bungau GS, Tit DM, Vesa CM, Jurca T, et al. Polypharmacy and drug-drug interaction architecture in hospitalized cardiovascular patients: insights from real-world analysis. Biomedicines. 2026;14(1):218. doi:10.3390/biomedicines14010218.
Open DOI Search in Google Scholar Back to article
Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J, et al. Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial. Circulation. 2024;149(21):1627–1638. doi:10.1161/CIRCULATIONAHA.124.069217.
Open DOI Search in Google Scholar Back to article
Cauwenberghs N, Sabovčik F, Magnus A, Haddad F, Kuznetsova T. Proteomic profiling for detection of early-stage heart failure in the community. ESC Heart Fail. 2021;8(4):2928–2939. doi:10.1002/ehf2.13375.
Open DOI Search in Google Scholar Back to article
Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5(9):755–768. doi:10.1038/nrd2038.
Open DOI Search in Google Scholar Back to article
Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054–e1091. doi:10.1161/CIR.0000000000000490.
Open DOI Search in Google Scholar Back to article
Rasooly D, Pereira AC, Joseph J. Drug discovery and development for heart failure using multi-omics approaches. Int J Mol Sci. 2025;26(6):2703. doi:10.3390/ijms26062703.
Open DOI Search in Google Scholar Back to article
Kotta PA, Nambi V, Bozkurt B. Biomarkers for heart failure prediction and prevention. J Cardiovasc Dev Dis. 2023;10(12):488. doi:10.3390/jcdd10120488.
Open DOI Search in Google Scholar Back to article
Dies RM, Jackson CN, Flanagan CJ, Sinnathamby ES, Spillers NJ, Potharaju P, et al. The evolving role of vericiguat in patients with chronic heart failure. Cureus. 2023;15(12):e49782. doi:10.7759/cureus.49782.
Open DOI Search in Google Scholar Back to article

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/rjc-2026-0025 | Journal eISSN: 2734-6382 | Journal ISSN: 1220-658X

Journal RSS Feed

Language: English

Published on: Sep 19, 2026

Published by: Romanian Society of Cardiology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

myocardial infarction,

heart failure,

vericiguat,

soluble guanylate cyclase

Related subjects:

Pediatrics and juvenile medicine,

Paediatric cardiology,

Surgery,

Cardiac surgery

© 2026 Jannat Atajanova, Shiraz Rafiq, Guiqiu Cao, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution 4.0 License.

AHEAD OF PRINT